Gossamer Bio Inc
Gossamer Bio Inc (GOSS) Historical Volatility
GOSS's 30 day historical volatility is 123.75%, in the 60th percentile of readings over the past year. This is an average percentile, meaning Gossamer Bio Inc shares have moved roughly in line with their typical range. GOSS's 30 day implied volatility sits at 210.91%, with an IV Rank of 42.26%, leaving IV 87.16 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 17, 2026.
Read more
Tracking GOSS historical volatility helps you see how much Gossamer Bio Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, GOSS's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor GOSS 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. GOSS's 30 day historical volatility, or GOSS HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing GOSS's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.
Historical Volatility
Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.
As of Nov 17, 2026
As of Nov 17, 2026
As of Nov 17, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →